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tion conditions. Adequate sedation was achieved in only 2 
patients (14%). Six patients (43%) needed additional propo-
fol to obtain adequate sedation. Chest wall rigidity occurred 
in 6 patients (43%).  Conclusions: The rapid administration of 
remifentanil provides insufficient sedation and is associated 
with a high risk of chest wall rigidity in preterm neonates. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 To prevent distress and adverse physiological respons-
es, traumatic damage and failed procedures, neonatal in-
tubation should always be performed with the use of pre-
medication  [1–3] . One of the most frequent reasons to 
intubate neonates is to administer surfactant for respira-
tory distress syndrome. During the INSURE (intubation, 
surfactant, extubation) procedure, patients are only brief-
ly intubated for the administration of surfactant and ex-
tubated immediately thereafter. To facilitate this rapid 
extubation, the premedication used should have a rapid 
onset and very short duration of action.
 A recent review on the use of premedication before 
intubation during the INSURE procedure showed no 
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 Abstract 
 Background: Neonatal intubation is stressful and should be 
performed with premedication. In the case of an INSURE (in-
tubation/surfactant/extubation) procedure a short duration 
of action of the premedication used is needed to facilitate 
fast extubation. Given its pharmacological profile, remifent-
anil seems a suitable candidate.  Objectives: The aim here 
was to evaluate the effect and side effects of remifentanil as 
a premedication for preterm neonates undergoing INSURE. 
 Methods: A prospective, single-center study in a level III neo-
natal intensive care unit was conducted. The quality of seda-
tion was assessed in preterm infants receiving remifentanil 
prior to intubation for the INSURE procedure. Intravenous 
remifentanil was administered quickly and followed by a sa-
line flush in approximately 30 s. The quality of sedation was 
defined by a combination of adequate sedation score, good 
intubation conditions and absence of side effects.  Results: 
The study was terminated after the inclusion of 14 patients 
because of the high rate of side effects and the poor intuba-
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conclusive evidence on the optimal premedication but 
stated that remifentanil was probably the best candidate 
because of its unique pharmacological profile  [4] . Remi-
fentanil has an extremely brief action, high predictability, 
rapid onset and offset of action, and immediate recovery 
of the clinical effect after interruption of the administra-
tion  [5] . The results of previous studies using remifent-
anil as single agent were also encouraging  [6–8] . We per-
formed an observational prospective study to evaluate the 
effects and side effects of remifentanil bolus infusion as 
premedication before the INSURE procedure and report 
here the results of implementing remifentanil into clini-
cal practice.
 Methods 
 Study Population 
 This prospective study was performed at the level III neonatal 
intensive care unit of the Erasmus MC Sophia Children’s Hospital 
in Rotterdam, the Netherlands. Before January 2013, surfactant 
was always administered during a period of conventional ventila-
tion and propofol was used as premedication before intubation. 
In January 2013 the standard of care was changed to performing 
the INSURE procedure for the administration of surfactant in all 
infants with a gestational age  ≥ 27 weeks and birth weight  ≥ 750 g. 
As premedication for the INSURE procedure we started to use 
remifentanil. Remifentanil was administered intravenously as a 
fast bolus and followed by an intravenous saline flush in 30 s. Af-
ter administration, the level of sedation was assessed with a stan-
dardized sedation score, performed by rubbing the sole of the pa-
tient’s foot and judging the motor reaction to that stimulus (1 = 
spontaneous movement; 2 = movement on slight touch; 3 = move-
ment in reaction to firm stimulus; 4 = no movement)  [9] . In case 
of inadequate sedation (score 1 or 2), another dose of remifentanil 
was administered according to the protocol. If sedation was ade-
quate (score 3 or 4), the procedure was continued. INSURE pro-
cedures were always performed by neonatologists and clinical fel-
lows experienced in neonatal intubations. As soon as the respira-
tory drive recovered after surfactant administration, the patient 
was extubated and commenced with nasal continuous positive 
airway pressure.
 Use of Remifentanil 
 Based on the results of the study by Avino et al.  [7] and our in-
experience with remifentanil, we decided to start with a low dose 
of 1 μg/kg. When sedation was inadequate, this dose could be re-
peated no more than twice (period 1). If sedation was still inade-
quate after 3 doses, the patient received propofol (1 mg/kg) and 
surfactant was administered in the conventional way. Because se-
dation was inadequate in 4 of the first 5 patients, the starting dose 
of remifentanil was increased to 2 μg/kg. When sedation was inad-
equate, another dose of remifentanil was given and each subse-
quent dose was increased with 1 μg/kg relative to the previous dose 
with a maximum dose of 5 μg/kg (period 2). If sedation was still 
insufficient, propofol (1 mg/kg) was given and surfactant was ad-
ministered in the conventional way.
 Outcome Measures 
 The primary outcome measure was the quality of sedation, de-
fined as the combination of an adequate sedation score, adequate 
intubation conditions and the absence of side effects. Intubation 
conditions were classified with a validated intubation score by rat-
ing laryngoscopy, vocal cords, coughing, jaw relaxation and limb 
movements ( table 1 )  [10] . Intubation conditions were good when 
the total score was  ≤ 10 with a score on each item  ≤ 2. Hypotension 
and chest wall rigidity were defined as side effects. Hypotension 
was defined as a mean blood pressure lower than gestational age 
and chest wall rigidity was defined as the inability to inflate with 
normal pressures. Secondary outcomes were the number of remi-
fentanil doses, maximum remifentanil dose, need for propofol to 
achieve adequate sedation and intubation attempts.
 Ethics Committee Approval 
 We received a waiver for ethical approval of the observational 
trial according to the Dutch Law of Research with Humans (No. 
2014.435; Medical Ethical Committee, Erasmus Medical Center, 
Rotterdam, The Netherlands).
 Results 
 Characteristics of Included Patients 
 Due to insufficient sedation and a high rate of side ef-
fects, the use of remifentanil was terminated after the in-
clusion of 14 patients: 5 patients in study period 1 and 9 
Item Score 1 Score 2 Score 3 Score 4
Laryngoscopy Easy Fair Difficult Impossible
Vocal cords Open Moving Closing Closed
Coughing None Slight Moderate Severe
Jaw relaxation Complete Slight Stiff Rigid
Limb movements None Slight Moderate Severe
From Viby-Mogensen et al. [10]
 Table 1.  Intubation score
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patients in study period 2. The baseline characteristics of 
the study patients and outcomes in study period 1 and 
study period 2 are reported in  table 2 . 
 Primary Outcome Measures 
 Adequate sedation was by the combination of 3 key 
components: adequate sedation score, adequate intuba-
tion conditions and the absence of side effects. This was 
achieved in only 2 patients (14%) of our total study popu-
lation. In study period 1, 2 patients had an adequate seda-
tion score but 1 of them had inadequate intubation con-
ditions despite this score. In the remaining 3 patients the 
sedation score was inadequate. Two of them were intu-
bated with propofol while the other was intubated despite 
the inadequate sedation score. None of the patients devel-
oped chest wall rigidity. In summary, adequate sedation 
based on the 3 key components was only achieved in 1 
patient in study period 1. In study period 2 adequate se-
dation scores after remifentanil were achieved in 6 pa-
tients. However, only 1 patient also had adequate intuba-
tion conditions and no side effects. One patient had inad-
equate intubation conditions and 4 patients developed 
chest wall rigidity. In 2 of these latter patients intubation 
failed or was never tried and propofol was administered. 
The sedation score was inadequate in 3 patients. In 2 of 
these patients propofol was used and 1 patient was intu-
bated despite an inadequate sedation score. Two of these 
3 patients developed chest wall rigidity. In summary, in 
study period 2 adequate sedation based on the 3 key com-
ponents was also only achieved in 1 patient.
 Chest wall rigidity was a frequently reported side ef-
fect, occurring in 6 patients (43%), all in study period 2 
(67% of patients in study period 2). Chest wall rigidity 
always occurred directly after the administration of remi-
fentanil and never after the administration of propofol. 
No other side effects such as hypotension were identified.
 Table 2.  Patient characteristics and study outcomes in study periods 1 and 2
Study period 1
(n = 5)
Study period 2
(n = 9)
Patient characteristics
Gestational age, weeks
Median
Range
29 2/7
28 0/7 to 35 0/7
28 3/7
27 3/7 to 32 0/7
Birth weight, g
Median
Range
1,320
920 – 2,200
1,130
910 – 1,860
Gender 1 male, 4 females 4 males, 5 females
Primary outcome measures – sedation parameters with remifentanil
Adequate sedation score (3 or 4) 2 (40) 6 (67)
Adequate intubation score (≤10) 2 (40) 4 (44)
Side effects (chest wall rigidity) 0 6 (67)
Adequate sedation 1 (20) 1 (11)
Secondary outcome measures
Doses of remifentanil
1
2
3
4
1 (20)
2 (40)
1 (20)
1 (20)
2 (22)
5 (56)
1 (11)
1 (11)
Propofol needed 2 (40) 4 (44)
Intubation attempts
1
2
3
Not reported
2 (40)
2 (40)
1 (20)
0
5 (56)
3 (33)
0
1 (11)
Outcome measures are presented as patients, n (%).
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 Secondary Outcome Measures 
 Overall, 6 patients (43%) needed propofol to reach ad-
equate sedation. In the 8 patients that achieved an ade-
quate sedation score with only remifentanil, 3 (38%) 
needed 1 dose, 4 (50%) received 2 doses and 1 (12%) re-
ceived 4 doses. The maximum dose was 1 μg/kg in 3 pa-
tients (38%), 2 μg/kg in 2 patients (25%) and 3 μg/kg in 
3 patients (38%).  Table 2 displays the number of remi-
fentanil doses in both study periods. Overall, intubation 
was successful at the first attempt in 54% of patients, 38% 
of patients required a second and 8% a third attempt. 
Four intubation attempts failed due to inadequate seda-
tion. 
 Discussion 
 We aimed to evaluate the effectiveness of remifent-
anil premedication for the INSURE procedure in pre-
term neonates. However, the results of our observation-
al study show that low doses (1 μg/kg) did not provide 
adequate sedation and rapidly administered remifent-
anil resulted in an unacceptable high incidence of chest 
wall rigidity following a high dose. Based on these re-
sults we conclude that remifentanil bolus infusion in
30 s is not suitable as a premedication for neonatal in-
tubation.
 Remifentanil as the single premedication drug has 
been investigated in 3 previous studies. Welzing et al.  [6] 
studied 2 μg/kg of remifentanil administered over 60 s 
in preterm infants undergoing the INSURE procedure. 
A single dose provided adequate sedation in 81% of the 
patients, with 19% needing a second dose and none of 
the patients requiring additional medication. Intubation 
was successful at the first attempt in 71% of the patients, 
insufficient sedation was never the reason for a second 
attempt and intubation conditions were excellent or 
good in all patients. No chest wall rigidity was reported. 
Avino et al.  [7] administered 1 μg/kg of remifentanil 
over 60 s to 36 preterm infants needing (semi)elective 
intubation and reported similar results to the previous 
study. Intubation was successful at the first attempt in 
75% of the patients but poor intubation conditions oc-
curred in 24% of the intubation attempts. Chest wall ri-
gidity occurred in 2 patients (6%). Choong et al.  [8] also 
investigated remifentanil in elective intubation in neo-
nates at a dose of 3 μg/kg administered over 60 s. They 
found less positive results, with additional medication 
needed in 26.7% of patients, failed first attempts in 60% 
of patients, and excellent or good intubation conditions 
in only 53.6% of patients. Chest wall rigidity was ob-
served in 13% of the patients. In our study, remifentanil 
was found to provide sufficient sedation in only a small 
number of patients. An explanation may be the faster 
infusion rate used in our study. Fast infusion is related 
to higher peak levels, and as a consequence increased 
side effects and shorter duration of effective sedation  [6, 
11] . The window of opportunity might have been too 
short to obtain an adequate sedation score and intuba-
tion procedure. We also found a significantly higher in-
cidence of chest wall rigidity, most likely also attribut-
able to the faster infusion rate of 30 s. In retrospect, the 
chosen duration of infusion was too fast in our study. 
We used an infusion rate of 30 s to flush the small vol-
ume of remifentanil because this is the standard way to 
administer many semiacute cardiorespiratory drugs in 
our intensive care. The results of the current study un-
derline the danger of such a routine way to administer 
drugs. Based on our results, this is obviously not appro-
priate and represents important knowledge for other cli-
nicians and researchers who intend to use remifentanil 
in preterm neonates.
 Our study has several limitations, including the small 
number of patients, no control group treated with an-
other sedative such as propofol, no blinding of doses and 
no pharmacokinetic analyses of remifentanil. However, 
our results are an important illustration of daily neona-
tal care. The combination of opioids with a hypnotic or 
sedative agent might be more appropriate than the use 
of a single agent. A slower infusion of remifentanil com-
bined with a low dose of propofol might by an interest-
ing combination to investigate in future studies.
 Conclusion 
 We conclude that remifentanil boluses administered 
in 30 s carry an unacceptably high risk of chest wall rigid-
ity in preterm neonates. Lower doses also provide insuf-
ficient sedation.
 Disclosure Statement 
 All authors have no conflicts of interest to declare.
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